FMP
Acumen Pharmaceuticals, Inc.
ABOS
NASDAQ
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
3.15 USD
-0.01 (-0.317%)
About
ceo
Mr. Daniel J. O'Connell M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://acumenpharm.com
exchange
NASDAQ
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
CIK
0001576885
ISIN
US00509G2093
CUSIP
00509G209
Address
427 Park Street
Phone
434 297 1000
Country
US
Employee
51
IPO Date
Jul 1, 2021
Key Executives
